Multiplexing Phenotype and Function for More Biologically Relevant Insights - 35

Related Article from

CAR T Cells Show Solid Progress
Josh P. Roberts
Tumors are Being Deprived of Cover by New CAR T-Cell Technologies
The lowest-hanging fruits of chimeric antigen receptor (CAR) T-cell therapy are
already being plucked. Yet even these fruits, which include Kite Pharma's Yescarta
and Novartis' Kymriah, cannot be described as easy pickings.
They obliged their developers to stretch their own capabilities while staying in
touch with the latest research findings. Nonetheless, Yescarta and Kymriah, both of
which are FDA-approved immunotherapies, are limited to treating hematological
tumors, or "liquid" tumors-as are many of the CAR T-cell therapies currently in
development. Such therapies spare developers the arduous climbing that awaits
those who would position CAR T-cell therapies to engage solid tumors.
CAR T cells have difficulty grappling with solid tumors several reasons: CAR T cells
may search in vain for a unique tumor-associated antigen; they may expire, fail to
proliferate, or simply languish, dawdling rather than converging on tumor sites;
they may struggle to cope with tumor cell heterogeneity and antigen loss; or they
may succumb to the immunosuppressive and metabolically hostile tumor microenvironment.
How might CAR T cells overcome these difficulties? That question was asked
repeatedly, in different contexts, by members of the cell therapy community who
participated in the CAR-T Congress: Maximizing the Potential of CAR-T Therapy.
At this event, provisional answers included novel infusion strategies, improved
targeting and control of CAR T cells, the adoption of alternative receptor technologies, and the generation of alternative CAR-carrying cells.
The most interesting suggestions from this event are summarized in this article. As
varied as these suggestions are, they all aim to combine two powers: the power of
an antibody to recognize its specific antigen, and the power of a T cell to deliver a
vigorous immune response.
35

| January, 2019

In a recent study that discussed the sustainability
of current drug discovery approaches, Dr. Stephan
and colleagues highlighted the key benefits and
challenges of high-content analysis for phenotypic
drug discovery.


http://www.genengnews.com

Multiplexing Phenotype and Function for More Biologically Relevant Insights

Table of Contents for the Digital Edition of Multiplexing Phenotype and Function for More Biologically Relevant Insights

Contents
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 1
Multiplexing Phenotype and Function for More Biologically Relevant Insights - Contents
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 3
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 4
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 5
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 6
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 7
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 8
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 9
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 10
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 11
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 12
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 13
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 14
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 15
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 16
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 17
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 18
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 19
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 20
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 21
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 22
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 23
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 24
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 25
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 26
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 27
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 28
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 29
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 30
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 31
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 32
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 33
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 34
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 35
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 36
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 37
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 38
https://www.nxtbookmedia.com